Activity Chair

Prem S. Subramanian, MD, PhD

Professor of Ophthalmology, Neurology, and Neurosurgery

University of Colorado School of Medicine

Vice Chair for Academic Affairs

Division Head, Neuro-Ophthalmology

University of Colorado Sue Anschutz-Rodgers Eye Center

Aurora, CO

Faculty

Rachel B. Brandstadter, MD

Assistant Professor of Clinical Neurology

Perelman School of Medicine

University of Pennsylvania

Corporal Michael J Crescenz VA Medical Center

Philadelphia, PA

Benjamin M. Greenberg, MD, MHS, FANA, FAAN, CRND

Distinguished Teaching Professor

Vice Chair for Clinical and Translational Research

Department of Neurology

Director, Perot Foundation Neurosciences Translational Research Center

O’Donnell Brain Institute

University of Texas Southwestern

Dallas, TX

Megan R. Weigel, DNP, ARNP-c, MSCN

Advanced Registered Nurse Practitioner

First Coast Integrative Medicine and Universal Neurological Care

Jacksonville, FL

Overview

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing autoimmune disease of the central nervous system that is characterized by inflammation in the optic nerve and spinal cord. Early stages of NMOSD are frequently misdiagnosed. Such diagnosis is typically based on the presence of key clinical characteristics, aquaporin-4 (AQP4) antibody status, and magnetic resonance imaging. The application of newer diagnostic criteria may assist in the earlier and more accurate diagnosis of NMOSD in those who may have been diagnosed with other diseases. Treatment options for NMOSD have been limited to date. Therefore, it would be important to examine current NMOSD treatments for their mechanisms of action, modes of administration, and clinical evidence regarding their safety and efficacy. In this continuing education symposium, experts in the field will present didactic information and cases, as well as engage in a panel discussion, to summarize evidence-based diagnostic criteria and best practices that aid in the differential diagnosis of NMOSD. This program will also differentiate current NMOSD therapeutics based on their mechanisms of action, efficacy, safety, and administration. Finally, faculty will also examine the interprofessional approaches to acute and long-term care patients with NMOSD.

BONUS – Be ready for our Rapid-Fire Roundtable, an engaging fast-paced exchange of clinical expert perspectives!

Agenda

6:15 PM Registration and Dinner

6:45 PM Introduction and Pretest

6:50 PM Understanding NMOSD: Burden and Diagnosis

7:00 PM Rapid-Fire Roundtable

7:05 PM Detecting NMOSD: What You Should Know

7:20 PM Case Presentation

7:28 PM Rapid-Fire Roundtable

7:35 PM NMOSD Treatment: A Novel Therapeutic Landscape

7:55 PM Case Presentation

8:03 PM Rapid-Fire Roundtable

8:10 PM Posttest and Question & Answer

8:15 PM Conclusion

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Assess the impact of NMOSD on patient quality of life.
• Evaluate best practices for the early detection and differential diagnosis of NMOSD.
• Examine current NMOSD treatments for their mechanisms of action, modes of administration, and clinical evidence regarding their safety and efficacy.
• Review interprofessional approaches to acute and long-term care of patients with NMOSD.

Target Audience

The intended audience for this activity is neurologists, nurses, pharmacists, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with or at risk for NMOSD.

This continuing medical education activity is provided by Vindico Medical Education.

This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.

This symposium is neither sponsored nor endorsed by the Consortium of Multiple Sclerosis Centers.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Vindico Medical Education will provide a maximum of 1.5 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This program is acceptable for 1.5 contact hours of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-22-009-L01-P, effective 06/03/2022. This is a knowledge-based activity, and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will be mitigated prior to the commencement of the activity.

Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.